| 1 |
32393046 |
10.1080/09603123.2020.1757043 |
2022 |
The expression of microRNAs and exposure to environmental contaminants related to human health: a review. |
TP53 |
| 2 |
33297669 |
10.3324/haematol.2020.267294 |
2022 |
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. |
TP53 |
| 3 |
34289655 |
10.3324/haematol.2021.278638 |
2022 |
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. |
TP53 |
| 4 |
34319003 |
10.1002/cnr2.1524 |
2022 |
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. |
TP53 |
| 5 |
34332791 |
10.1016/j.pathol.2021.04.008 |
2022 |
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax. |
TP53 |
| 6 |
34560683 |
10.1097/PAS.0000000000001813 |
2022 |
A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients. |
TP53 |
| 7 |
34608246 |
10.1038/s41379-021-00909-4 |
2022 |
Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. |
TP53 |
| 8 |
34664256 |
10.1111/bjh.17894 |
2022 |
Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. |
TP53 |
| 9 |
34764434 |
10.1038/s41379-021-00962-z |
2022 |
BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. |
TP53 |
| 10 |
34788985 |
10.3324/haematol.2021.279631 |
2022 |
Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing. |
TP53 |
| 11 |
34791836 |
10.1002/cam4.4422 |
2022 |
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. |
TP53 |
| 12 |
34842019 |
10.1080/10428194.2021.2008383 |
2022 |
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole? |
TP53 |
| 13 |
34861697 |
10.1182/bloodadvances.2021006156 |
2022 |
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. |
TP53 |
| 14 |
34882582 |
10.1172/JCI153283 |
2022 |
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. |
TP53 |
| 15 |
34951009 |
10.1111/bjh.17971 |
2022 |
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. |
TP53 |
| 16 |
35030632 |
10.1182/bloodadvances.2021006410 |
2022 |
Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. |
TP53 |
| 17 |
35106936 |
10.1002/cam4.4550 |
2022 |
SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. |
TP53 |
| 18 |
35151528 |
10.1016/j.blre.2022.100930 |
2022 |
CLL update 2022: A continuing evolution in care. |
TP53 |
| 19 |
35240014 |
10.4143/crt.2022.017 |
2022 |
Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. |
TP53 |
| 20 |
35266562 |
10.1002/ajh.26523 |
2022 |
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. |
TP53 |
| 21 |
35327381 |
10.3390/biomedicines10030579 |
2022 |
Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma. |
TP53 |
| 22 |
35344582 |
10.1182/blood.2021014007 |
2022 |
Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies. |
TP53 |
| 23 |
35356636 |
10.14740/jh942 |
2022 |
Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma. |
TP53 |
| 24 |
35417939 |
10.3324/haematol.2021.280352 |
2022 |
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. |
TP53 |
| 25 |
35435617 |
10.1007/s11864-022-00953-5 |
2022 |
Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T. |
TP53 |
| 26 |
35437610 |
10.1007/s00277-022-04795-x |
2022 |
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant. |
TP53 |
| 27 |
35452696 |
10.1016/j.humpath.2022.04.002 |
2022 |
B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas. |
TP53 |
| 28 |
35511481 |
10.1080/09553002.2022.2074164 |
2022 |
<i>BAG1, MGMT, FOXO1</i>, and <i>DNAJA1</i> as potential drug targets for radiosensitizing cancer cell lines. |
TP53 |
| 29 |
35561314 |
10.1182/bloodadvances.2022007247 |
2022 |
Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. |
TP53 |
| 30 |
35562412 |
10.1038/s41379-022-01085-9 |
2022 |
Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. |
TP53 |
| 31 |
35577753 |
10.1016/j.clml.2022.04.017 |
2022 |
SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation. |
TP53 |
| 32 |
35657404 |
10.1007/s00428-022-03342-3 |
2022 |
Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma. |
TP53 |
| 33 |
35726023 |
10.1038/s41684-022-00998-x |
2022 |
The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications. |
TP53 |
| 34 |
35757723 |
10.3389/fimmu.2022.894787 |
2022 |
Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy. |
TP53 |
| 35 |
35760783 |
10.1038/s41419-022-05021-2 |
2022 |
IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma. |
TP53 |
| 36 |
35794096 |
10.1038/s41467-022-31355-8 |
2022 |
Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. |
TP53 |
| 37 |
35882439 |
10.1182/bloodadvances.2022007541 |
2022 |
Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association. |
TP53 |
| 38 |
35953760 |
10.1631/jzus.B2200016 |
2022 |
HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. |
TP53 |
| 39 |
35964234 |
10.1093/ajcp/aqac087 |
2022 |
Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma. |
TP53 |
| 40 |
35968590 |
10.3760/cma.j.issn.0253-2727.2022.06.006 |
2022 |
[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review]. |
TP53 |
| 41 |
36029326 |
10.1007/s00277-022-04914-8 |
2022 |
Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis. |
TP53 |
| 42 |
36055572 |
10.1016/j.clim.2022.109105 |
2022 |
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. |
TP53 |
| 43 |
32732362 |
10.3324/haematol.2020.254276 |
2021 |
Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1. |
TP53 |
| 44 |
32961552 |
10.1182/blood.2020007507 |
2021 |
Mutational landscape of gray zone lymphoma. |
TP53 |
| 45 |
32973328 |
10.1038/s41379-020-00685-7 |
2021 |
The clinicopathological and molecular features of sinusoidal large B-cell lymphoma. |
TP53 |
| 46 |
33263441 |
10.1080/17474086.2021.1856652 |
2021 |
Development of molecular intervention strategies for B-cell lymphoma. |
TP53 |
| 47 |
33303420 |
10.1016/j.clml.2020.10.009 |
2021 |
Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study. |
TP53 |
| 48 |
33306126 |
10.1093/jmcb/mjaa065 |
2021 |
BCL7C suppresses ovarian cancer growth by inactivating mutant p53. |
TP53 |
| 49 |
33311649 |
10.1038/s41379-020-00720-7 |
2021 |
Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. |
TP53 |
| 50 |
33395752 |
10.1016/j.tranon.2020.100977 |
2021 |
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. |
TP53 |
| 51 |
33414134 |
10.1158/1078-0432.CCR-20-2378 |
2021 |
Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP. |
TP53 |
| 52 |
33454909 |
10.1007/s11033-021-06136-z |
2021 |
Deciphering the molecular pathways of apoptosis using purified fractions from leaf extract of Basella alba through studying the regulation of apoptosis related genes. |
TP53 |
| 53 |
33561953 |
10.3390/cancers13040650 |
2021 |
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. |
TP53 |
| 54 |
33735664 |
10.1016/j.neo.2021.02.002 |
2021 |
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. |
TP53 |
| 55 |
33747936 |
10.3389/fonc.2021.622648 |
2021 |
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. |
TP53 |
| 56 |
33775465 |
10.1016/j.blre.2021.100824 |
2021 |
Revisiting Richter transformation in the era of novel CLL agents. |
TP53 |
| 57 |
33777778 |
10.3389/fonc.2021.628807 |
2021 |
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. |
TP53 |
| 58 |
33808787 |
10.3390/cancers13061414 |
2021 |
EBV and the Pathogenesis of NK/T Cell Lymphoma. |
TP53 |
| 59 |
33902665 |
10.1186/s13045-021-01054-w |
2021 |
Current and future treatment strategies in chronic lymphocytic leukemia. |
TP53 |
| 60 |
33945543 |
10.1371/journal.pone.0248886 |
2021 |
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes. |
TP53 |
| 61 |
33946435 |
10.3390/cancers13092167 |
2021 |
Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma. |
TP53 |
| 62 |
33951889 |
10.3324/haematol.2020.271957 |
2021 |
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. |
TP53 |
| 63 |
33972504 |
10.1038/s41408-021-00477-5 |
2021 |
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. |
TP53 |
| 64 |
34080947 |
10.1080/10428194.2021.1933480 |
2021 |
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets. |
TP53 |
| 65 |
34113336 |
10.3389/fimmu.2021.599493 |
2021 |
<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report. |
TP53 |
| 66 |
34221962 |
10.3389/fonc.2021.638154 |
2021 |
Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma. |
TP53 |
| 67 |
34248972 |
10.3389/fimmu.2021.687458 |
2021 |
Targeting Bruton's Tyrosine Kinase in CLL. |
TP53 |
| 68 |
34256839 |
10.1186/s40164-021-00232-3 |
2021 |
Progress in molecular feature of smoldering mantle cell lymphoma. |
TP53 |
| 69 |
34272731 |
10.1111/bjh.17708 |
2021 |
EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. |
TP53 |
| 70 |
34320163 |
10.1182/blood.2020006783 |
2021 |
Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. |
TP53 |
| 71 |
34339834 |
10.1016/j.critrevonc.2021.103430 |
2021 |
Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review. |
TP53 |
| 72 |
34350060 |
10.1080/2162402X.2021.1928365 |
2021 |
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. |
TP53 |
| 73 |
34374220 |
10.1002/cjp2.223 |
2021 |
c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma. |
TP53 |
| 74 |
34381423 |
10.3389/fendo.2021.673908 |
2021 |
Case Report: Identification of Potential Prognosis-Related <i>TP53</i> Mutation and <i>BCL6-LPP</i> Fusion in Primary Pituitary Lymphoma by Next Generation Sequencing: Two Cases. |
TP53 |
| 75 |
34478505 |
10.1182/bloodadvances.2021005083 |
2021 |
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. |
TP53 |
| 76 |
34500472 |
10.1182/bloodadvances.2021004528 |
2021 |
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. |
TP53 |
| 77 |
34568060 |
10.3389/fonc.2021.729106 |
2021 |
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia. |
TP53 |
| 78 |
34570179 |
10.1182/bloodadvances.2021004668 |
2021 |
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. |
TP53 |
| 79 |
34576319 |
10.3390/ijms221810157 |
2021 |
BH3 Mimetics in Hematologic Malignancies. |
TP53 |
| 80 |
34625994 |
10.1002/ajh.26367 |
2021 |
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. |
TP53 |
| 81 |
34627430 |
10.19746/j.cnki.issn.1009-2137.2021.05.019 |
2021 |
[Clinical Characteristics and Prognosis Affecting-Factors of the Patients with Burkitt Lymphoma]. |
TP53 |
| 82 |
34680290 |
10.3390/cancers13205141 |
2021 |
Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents. |
TP53 |
| 83 |
34806851 |
10.20892/j.issn.2095-3941.2021.0193 |
2021 |
Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP. |
TP53 |
| 84 |
34830747 |
10.3390/cancers13225592 |
2021 |
Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. |
TP53 |
| 85 |
34925435 |
10.3389/fgene.2021.677650 |
2021 |
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing. |
TP53 |
| 86 |
34926267 |
10.3389/fonc.2021.765544 |
2021 |
<i>SEPT6</i>_<i>TRIM33</i> Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas. |
TP53 |
| 87 |
31537689 |
10.3324/haematol.2018.214056 |
2020 |
<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. |
TP53 |
| 88 |
31738823 |
10.1182/blood.2019002699 |
2020 |
Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. |
TP53 |
| 89 |
31774495 |
10.1182/blood.2019001904 |
2020 |
Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. |
TP53 |
| 90 |
31822801 |
10.1038/s41379-019-0415-5 |
2020 |
Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America. |
TP53 |
| 91 |
31918102 |
10.1016/j.chemosphere.2019.125794 |
2020 |
Antagonistic effect of selenium on lead-induced neutrophil apoptosis in chickens via miR-16-5p targeting of PiK3R1 and IGF1R. |
TP53 |
| 92 |
31991488 |
10.1111/apm.13029 |
2020 |
EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma. |
TP53 |
| 93 |
32064880 |
10.4149/neo_2020_190307N194 |
2020 |
KMT2D and TP53 mutation status improve the prognostic value of the International Prognostic Index (IPI) stratification in ENKTL patients. |
TP53 |
| 94 |
32160292 |
10.1182/blood.2019002385 |
2020 |
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. |
TP53 |
| 95 |
32239385 |
10.1007/s11523-020-00710-4 |
2020 |
Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib. |
TP53 |
| 96 |
32239765 |
10.1002/ajh.25796 |
2020 |
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. |
TP53 |
| 97 |
32253666 |
10.1007/s12185-020-02867-0 |
2020 |
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? |
TP53 |
| 98 |
32272636 |
10.3390/cancers12040894 |
2020 |
An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. |
TP53 |
| 99 |
32321318 |
10.1080/13543784.2020.1760245 |
2020 |
Novel agents for mantle cell lymphoma: molecular rational and clinical data. |
TP53 |
| 100 |
32399964 |
10.1002/ijc.33049 |
2020 |
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. |
TP53 |
Datasets
Models
